Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10661studies shown

Showing 8,761-8,772 of 10,661

Drug study icon

CompletedNCT05076370

Safety and Tolerability of Cannabidiol Among Persons With Addiction Receiving Methadone or Buprenorphine

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 18 Years to 70 Years

Countries: United States
Sponsor: Yale University
Condition: Addiction

Drug study icon

TerminatedNCT01900522

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugOver 18 Years

Countries: United States
Sponsor: Takeda
Condition: Schizophrenia

Drug study icon

CompletedNCT03238326

Open-Label Flexible-dose Brexpiprazole for schizophrenia

This study is completed in the United States, in France, in Italy, .... It is testing Open-Label Flexible-dose Brexpiprazole for schizophrenia.

In United States

SchizophreniaDrugFrom 13 Years to 17 Years

Countries: United States, France, Italy, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT02773576

Safety and Tolerability of Risperidone Implants

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 70 Years

Countries: United States
Sponsor: Braeburn Pharmaceuticals
Condition: Schizophrenia

Drug study icon

CompletedNCT04187560

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: LB Pharmaceuticals Inc.
Condition: Schizophrenia

Drug study icon

TerminatedNCT00265382

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 13 Years to 17 Years

Countries: United States, Colombia, Costa Rica, ...
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT00265330

Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolarity type I (Manic or Mixed)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugFrom 10 Years to 17 Years

Countries: United States
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition: Bipolarity

Drug study icon

CompletedNCT00640419

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 6 Years to 12 Years

Countries: United States
Sponsor: AbbVie (prior sponsor, Abbott)
Condition: ADHD

Drug study icon

TerminatedNCT04987762

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 4 Years to 12 Years

Countries: United States
Sponsor: Purdue Pharma LP
Condition: ADHD

Drug study icon

CompletedNCT01909466

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 64 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Behavioral study icon

CompletedNCT02510014

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Addiction

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionBehavioralFrom 18 Years to 65 Years

Countries: United States
Sponsor: Indivior Inc.
Condition: Addiction

Drug study icon

CompletedNCT00044005

Safety and Tolerability Study of Drug to Treat Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Sumitomo Pharma America, Inc.
Condition: Schizophrenia

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.